

### METRICS

**Oncobiomed (OBM)** has developed two immunotherapy technologies against cancer:

**TAPCells™** technology applied to more than 300 patients with highly successful results.

**Lycellvax** generic vaccine with a centralized manufacturing model and simple production.


**TAPCells™ and Lycellvax.** These biological vaccines stimulate and activate patient's immune system, generating a specific response against melanoma tumors, prostate cancer, and other types.

### DESCRIPTION




Prostate cancer is globally one of the most common cancers in men. Nearly 300 thousand new cases are detected yearly, out of which 41 thousand are fatal. While melanoma is the most lethal skin cancer, being estimated there will be nearly 280 thousand new cases and more than 67 thousand deaths caused by it.

### SOLUTION

1. **TAPCells™** (Tumor Antigen-Presenting Cells) are immune system cells generated ex vivo having similar characteristics as dendritic cells which, in physiological conditions, can present tumor antigens to T-lymphocytes, triggering a specific immune response against cancer. This technology is classified as personalized medicine, since TAPCells™ production is carried out from each patient's peripheral blood, obtaining monocytes which are stimulated with cytokines to get an extract of tumor cells (TRIMEL™). After finishing the process, TAPCells™ are inoculated to the patient subcutaneously. This technology has been studied in melanoma in clinical trials Phase I and in two clinical trials Phase II, which results have been published in scientific journals.



**2. Lycellvax** is a new immunogenic formulation developed internally by Oncobiomed. It is based on the use of heat-treated cell lysates coming from highly selected cell lines of allogeneic melanoma and from other solid tumors, combined with an adjuvant derived from haemolymphs to trigger an *in vivo* direct stimulation of the immune system in patients with cancer (melanoma and colon cancer, among others). Thus, a generic vaccine is generated with a centralized and independent manufacturing model of each patient. Lycellvax has been tested at a pre-clinical level, in terms of its safety as well as its efficiency, in murine models of melanoma and colon carcinoma, additionally developing immunogenic formulation for other types of cancer, such as prostate, kidney and gallbladder.



## PROTECTION

TAPCells™	Patent granted
USA	Nº 9,694,059
Australia	Nº 2008303453
Israel	Nº 204821
Mexico	Nº /2010/003415
New Zealand	Nº 584606
Chile	Nº 51,370
Brasil	Nº 0817535-7 (Patent pending)

**Lycellvax** patent application PCT

PCT/IB2020/051906

The intellectual property of both technologies belongs to the University of Chile. However, Oncobiomed has signed licensed contracts with the university for both technologies, for the national and international market.

## MARKET

Market size: USD 4,07 billions (2017).  
 CAGR: 17,7%.  
 Segment: Cancer vaccines (global).  
 Expected market size: USD 12,81 billions (2023).

## BUSINESS MODEL

Licensing TAPCells™ and Lycellvax to companies with production capacity of technologies, commercialization and distribution, as the Pharmaceutical Industry.



Biotechnology company  
 Founded in 2005  
[www.oncobiomed.cl](http://www.oncobiomed.cl)

## TEAM



**Cristián Pereda**  
 Molecular Biotechnology  
 Engineering



**Flavio Salazar**  
 Inventor & Scientific Advisor PhD in  
 Medical Sciences



**Juan Pablo Miranda**  
 Chief clinical officer  
 MD oncologist



**Elena Valderas**  
 Legal advisor  
 Lawyer

**Contact : Jovanka Trebotich,**  
 Technology Transfer Coordinator  
[jovanka.trebotich@knowhub.cl](mailto:jovanka.trebotich@knowhub.cl)  
 Tel. +56 22 3895600

